Univercells a biologics manufacturing specialist based in Belgium, specialising in providing innovative, low-cost, high-density biomanufacturing solutions. It focuses on streamlining and scaling the production of biopharmaceuticals, including vaccines, antibodies, and proteins.

Founded in 2013, Univercells delivers end-to-end biomanufacturing services through cutting-edge technology. The company combines high-efficiency single-use technologies with continuous production processes, enabling significant cost reductions for clients. This approach helps cut production costs by up to 90% and investment requirements by 75%, making it an attractive option for biotech companies aiming to scale up production efficiently.

Key Products and Services:

• Biomanufacturing Solutions: End-to-end services for the production of antibodies, proteins, and vaccines.
• Cell Culture under Perfusion: High-density cell culture systems for efficient bioprocessing.
• Clarification and Capture: Advanced systems for purifying proteins and biologics.
• Single-Use Technologies: Providing scalable, flexible manufacturing capabilities for biotech firms.
• Process Design and Technology Transfer: Offering expertise in process design, tech transfer, and facility construction.
• Facility Construction and Training: Comprehensive support, from the design of clinical plans to training staff in advanced biomanufacturing techniques.

Univercells positions itself as a global partner in biomanufacturing, with a strategic focus on reducing production costs and time-to-market for its clients. Through its subsidiary, Exothera, the company further extends its capabilities in viral vector production, aiming to revolutionise the manufacturing of advanced therapies.